Friday, 16 October 2026European Markets

MCPHY ENERGY Stock Impressive Rise On Monday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with mcphy energy (mcphy.pa) rising 13.01% to €3.74 on monday, after two consecutive sessions in a row of gains. cac 40 slid 0.37% to €7,568.86, after two successive sessions in a row of gains, on what was a somewhat negative trend trading session today.

mcphy energy's last close was €3.31, 77.81% below its 52-week high of €14.90.

about mcphy energy

mcphy energy s.a. provides hydrogen production and distribution equipment for hydrogen energy, hydrogen mobility, and industrial hydrogen markets. the company offers alkaline electrolyzers; hydrogen storage and transportation solutions; and fuel cell systems. it also develops hydrogen stations; and provides integrated hydrogen solutions. the company operates in europe, the middle east, africa, the americas, and the asia pacific. mcphy energy s.a. was incorporated in 2007 and is headquartered in grenoble, france.

earnings per share

as for profitability, mcphy energy has a trailing twelve months eps of €-1.51.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -31.8%.

revenue growth

year-on-year quarterly revenue growth grew by 34.9%, now sitting on 17.88m for the twelve trailing months.

volatility

mcphy energy's last week, last month's, and last quarter's current intraday variation average was a negative 0.40%, a negative 0.85%, and a positive 2.74%.

mcphy energy's highest amplitude of average volatility was 2.78% (last week), 2.28% (last month), and 2.74% (last quarter).

more news about mcphy energy (mcphy.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com